We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&I") space. Helping patients and their families is the guiding principle at the heart of Barinthus Bio.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$42M
▼ -8.8% YoY
Op. Margin
–
ROIC
-42.34%
▼ -17.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▼ -61.0% YoY
Op. Cash Flow (TTM)
-$26M
▼ -65.8% YoY
Net Debt
-$49M
Net Cash Position
Cash & Equiv.
$59M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BRNS
Barinthus Biotherapeutics (BRNS) in three numbers
Questions about Barinthus Biotherapeutics
Is Barinthus Biotherapeutics a high-quality business?
Barinthus Biotherapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$49M, and its weakest is return on capital at -42.3%. The Quality tab shows every check against its target.
Does Barinthus Biotherapeutics (BRNS) pay a dividend?
No. Barinthus Biotherapeutics (BRNS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 18 Sept 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BRNS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BRNS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.